Article
Biochemistry & Molecular Biology
Mariafausta Fischietti, Frank Eckerdt, Gavin T. Blyth, Ahmet D. Arslan, William M. Mati, Chidera Oku, Ricardo E. Perez, Catalina Lee-Chang, Ewa M. Kosciuczuk, Diana Saleiro, Elspeth M. Beauchamp, Maciej S. Lesniak, Daniela Verzella, Leyu Sun, Eleanor N. Fish, Guang-Yu Yang, Wenan Qiang, Leonidas C. Platanias
Summary: SLFN5 is overexpressed in human pancreatic ductal adenocarcinoma (PDAC) and correlates with worse outcomes, targeted deletion of SLFN5 can inhibit PDAC cell proliferation and tumorigenesis, it promotes transcription of key genes that stimulate S phase progression by binding/blocking E2F7.
Review
Pharmacology & Pharmacy
Wanting Hou, Biao Yang, Hong Zhu
Summary: Nanoparticle-based therapeutic strategies have shown promising applications in improving drug delivery and reversing the immunosuppressive tumor microenvironment for PDAC immunotherapy.
Review
Pharmacology & Pharmacy
Alexander G. Raufi, Nicholas R. Liguori, Lindsey Carlsen, Cassandra Parker, Liz Hernandez Borrero, Shengliang Zhang, Xiaobing Tian, Anna Louie, Lanlan Zhou, Attila A. Seyhan, Wafik S. El-Deiry
Summary: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with slow progress towards effective therapy, indicating an urgent need for novel treatment approaches, with autophagy potentially being a promising therapeutic target.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Mundla Srilatha, Ramarao Malla, Megha Priya Adem, Jeremy B. Foote, Ganji Purnachandra Nagaraju
Summary: Obesity is closely associated with pancreatic health, and obese individuals have an increased risk for developing pancreatic ductal adenocarcinoma (PDAC). Factors such as chronic inflammation, insulin resistance, metabolic dysfunction, immune suppression, hormone level changes, and genetic mutations contribute to the development and progression of PDAC in obese individuals.
SEMINARS IN CANCER BIOLOGY
(2023)
Article
Oncology
Jiatong Wang, Chi Hin Wong, Yinxin Zhu, Xiaoqiang Yao, Kelvin K. C. Ng, Chengzhi Zhou, Ka Fai To, Yangchao Chen
Summary: The study identifies GRIN2D as a potential therapeutic target for pancreatic ductal adenocarcinoma (PDAC) and demonstrates its oncogenic role in PDAC progression.
BIOMARKER RESEARCH
(2023)
Review
Oncology
Hannah Pook, Siim Pauklin
Summary: Pancreatic cancer is highly deadly, with current treatments facing various challenges such as late diagnosis, immunologically cold phenotype, and difficulty in distinguishing beneficial drug targets. Recent progress includes identifying mFOLFIRINOX as a standard-of-care adjuvant therapy and discovering KRAS(G12C) mutant inhibitors, with promising new approaches targeting the tumor microenvironment, enhancing immunotherapies, epigenetic modulation, and destruction of CSCs.
Review
Oncology
Maxime Lafond, Thomas Lambin, Robert Andrew Drainville, Aurelien Dupre, Mathieu Pioche, David Melodelima, Cyril Lafon
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal form of cancer with poor prognosis. Focused ultrasound is an emerging therapy that shows promising potential in treating PDAC. This review provides an overview of the clinical application and scientific research of therapeutic focused ultrasound for PDAC, summarizing its current benefits, challenges, and future directions.
Review
Cell Biology
Mehran Taherian, Hua Wang, Huamin Wang
Summary: This review provides an overview of the histological and molecular heterogeneity of pancreatic ductal adenocarcinoma (PDAC), as well as its subtypes, precursor lesions, immunosuppressive tumor microenvironment (TME), and available predictive molecular markers.
Article
Oncology
An-Dong Liu, Jie Zhou, Xiao-Yang Bi, Guo-Qing Hou, Shawn Shun-Cheng Li, Qing Chen, Hui Xu, Xuan Cao
Summary: The XQ-2d-SH2 CM-(Arg)9 conjugate shows potent efficacy in treating PDAC by blocking pY-related signaling pathways, inhibiting proliferation and metastasis of cancer cells, and eliminating the dense stroma of tumors.
CLINICAL AND TRANSLATIONAL MEDICINE
(2021)
Review
Gastroenterology & Hepatology
Aditi Jain, Vikas Bhardwaj
Summary: Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related deaths in the United States. This review discusses the molecular mechanisms involved in therapy resistance in PDAC, current approaches in targeting these mechanisms, lessons learned from the failure of immunotherapy in PDAC, and ongoing efforts to improve tumor's immunological response.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Review
Biochemistry & Molecular Biology
Gitika Thakur, Raj Kumar, Saet-Byul Kim, Sang-Yeob Lee, Sung-Lim Lee, Gyu-Jin Rho
Summary: Pancreatic cancer is a severe and devastating disease, with the main factor contributing to tumor development and resistance being pancreatic cancer stem cells (PCSCs). Stem cells, particularly mesenchymal stem cells (MSCs), are considered influential anti-cancer agents that control the pancreatic tumor microenvironment through anti-inflammatory actions and activation of host immune cells.
Review
Oncology
Vida Karimnia, Frank J. Slack, Jonathan P. Celli
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with current clinical trials showing limited improvements in patient survival. Photodynamic therapy (PDT) has emerged as a potential approach for treating pancreatic tumors based on studies indicating its effectiveness in activating photosensitizing agents in target tissues.
Review
Oncology
Daniel R. Principe, Patrick W. Underwood, Murray Korc, Jose G. Trevino, Hidayatullah G. Munshi, Ajay Rana
Summary: Pancreatic ductal adenocarcinoma (PDAC) has poor prognosis, mainly due to late diagnosis, multi-drug resistance, and associated toxicities of chemotherapy. Current treatments are not very effective, highlighting the need to improve understanding of factors limiting efficacy in order to enhance patient survival and quality of life.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Niklas Sturm, Thomas J. Ettrich, Lukas Perkhofer
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a challenging cancer to treat due to late diagnosis and poor prognosis. Various molecules have been identified as biomarkers, providing potential for early diagnosis and therapeutic prediction. Progress has been made in predicting therapy response with biomarkers, but early detection and recurrence still require further research.
Article
Oncology
Christopher M. Thompson, Andrew Cannon, Sean West, Dario Ghersi, Pranita Atri, Rakesh Bhatia, Lynette Smith, Satyayanarayana Rachagani, Christopher Wichman, Sushil Kumar, Surinder K. Batra
Summary: This study analyzed the expression of mucin family members and their splice variants in PDAC tumors, identified four novel mucin-based PDAC subtypes, and validated the association of MUC1, MUC4, and MUC16 SVs with PDAC patient survival.
CLINICAL CANCER RESEARCH
(2021)